It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tufts University Medical Center, Clinical & Translational Science Institute, Boston, USA (GRID:grid.67033.31) (ISNI:0000 0000 8934 4045); Evidation Health, 167 2nd Ave, San Mateo, USA (GRID:grid.492625.e); Cambridge Innovation Center, Eli Lilly and Company, Cambridge, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544)
2 Cambridge Innovation Center, Eli Lilly and Company, Cambridge, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544); Massachusetts Institute of Technology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
3 Cambridge Innovation Center, Eli Lilly and Company, Cambridge, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544); Novartis Pharmaceuticals, East Hanover, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)
4 Tufts University Medical Center, Clinical & Translational Science Institute, Boston, USA (GRID:grid.67033.31) (ISNI:0000 0000 8934 4045); Novartis Pharmaceuticals, East Hanover, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)